As they lay dying: Medicare rules rob voiceless ALS patients of the ability to ...

PBS NewsHour - 2 days ago
The devices were shipped in what...

'Right to try' laws no guarantee patient will get experimental drugs - 3 days ago
Its maker reported that it...

Al's Beef to Unveil Secret Fan-Inspired Menu at Private Tasting Event

NBC Chicago (blog) - 2 days ago
The list of new food items will...

Factbox: How companies are mining patient DNA, data for drugs

Yahoo News - 1 week ago
--Pfizer Inc in January announced...

Helmet Sensors Try to Answer if Football Can Ever Be Safe

Newsweek - 3 weeks ago
Many football players'...

Central Valley's growing concern: Crops raised with oilfield water

Midland Reporter-Telegram - 2 weeks ago
But experts say that testing of...

The Role of Herbs and Spices in Cancer Prevention

Cancer - 2 days ago
NCI's cancer Biomedical...

How companies are mining patient DNA, data for drugs

Daily Mail - 1 week ago
--Pfizer Inc in January announced...

American Foundation for the Blind honors Apple for VoiceOver technology

9 to 5 Mac (blog) - 2 weeks ago
Apple received an AFB Access Award...

Tomorrow's Cures Today: Let's liberate medicine in America. Here's our vision ...

Fox News - 3 weeks ago
Moreover, as of today, there is no...

News via Google. See more news matching 'als expanded access'


Expanded Access

Bringing Research and Patients Together

Our Expanded Access platform is meant to do two things:

  1. Empower patients with access to new treatments that are in clinical research.
  2. Empower further research with clinical data from those patients.

For someone with a quick-killer disease, participating in clinical research may be the only way to access a new medicine that might help him live longer.  He may be willing to accept some uncertainty, considering the alternative.  So for patients, there’s a lot of overlap between treatment exploration and research.

But what about patients who cannot get into clinical trials?  Can they still take part in research and explore investigational treatment?

Yes, they can, but only through what are called Expanded Access programs (EAPs).  These are meant to include a much broader group of patients than traditional clinical trials, sometimes exclusively those patients who don’t meet clinical trial enrollment criteria or who otherwise cannot get into trials.

ALS-ETF is bringing a new kind of Expanded Access to the ALS community, to make a groundbreaking impact in the treatment landscape for patients as well as the research that’s powered by patient data.

Learn more about Expanded Access programs here.

Learn more about our research goals here.